Coherus Biosciences Inc
Research Coherus Biosciences Inc (CHRS) on Bullrun: market cap USD 223.66M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCHRS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 223.66M
- Financial periodFY2025
- RevenueUSD 42.17M
- Revenue growth59.8%
- Net incomeUSD 168.02M
- Gross margin67.2%
Valuation Snapshot
latest market cap is USD 223.66M.
About Coherus Biosciences Inc
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Frequently asked questions
What is Coherus Biosciences Inc's market cap?
Coherus Biosciences Inc's market capitalization is USD 223.66M.
What does Coherus Biosciences Inc do?
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor;